MBX Capital is a venture capital partnership investing in early-stage healthcare, life sciences, and environmental health companies

MBX Capital

Village Global is an early stage venture capital firm backed by some of the world's most successful entrepreneurs.

Village Global

We provide early-growth stage capital to transformational venture-backed technology businesses.We believe in partnering with the very best entrepreneurs and top-tier early-stage investors to help build enduring technology companies. We operate under the premise that the only way to build a world class business is to always put the company first. We believe this ethos optimizes outcomes for our companies and Limited Partners alike.

Beni VC

Startup Yale in an entrepreneurship program that offers funding, mentorship, and networking opportunities for enthusiastic innovators.

Startup Yale

Psymed Ventures is an investment syndicate that invests in early-stage psychedelics companies. The firm was founded in 2020 by Matias Serebrinsky and Dina Burkitbayeva and is headquartered in San Francisco, California, United States.

PsyMed Ventures

Empath Ventures is a venture capital firm that mainly invests in psychedelic medicine companies. The firm specializes in the fields of investment financial services, finance, and venture capital. It was founded in 2021 and headquartered in Los Angeles California.

Empath Ventures

What do Peter Thiel, Kevin O’Leary, Tim Ferris, Sam Harris, Michael Pollan, Sting, and Tony Robbins all have in common? They are either advocates for or directly investing in psychedelic medicine and research.  The past decade has ushered in a psychedelic renaissance, inspiring a massive push for research, decriminalization, and legalization of these powerful substances. There has been a radical shift in discussions of consciousness expansion, which has broken into the mainstream. With newfound, burgeoning support ranging from academia to medicine, government to business, there’s an extraordinary opportunity to tap into the commercial and social potential of this nascent space.  Mystic Ventures believes the world would be much better if more people experienced the healing power of psychedelics. Mystic cares about mental health and human conditions. The fund’s goal is to draw on my experience as an entrepreneur and investor, backing pre-seed and seed-stage startups creating high-quality psychedelic experiences and treatments. I am starting Mystic to support founders who realize the healing power of psychedelics to elevate humanity’s consciousness. I will harness my broad network and abundance of resources to ensure the success of these ventures. Given my reach throughout the investing world and social media, as well as a growing network within the psychedelic space, I am confident that we will have outstanding deal flow and access to any emerging opportunities. We will draw on a wide range of industry experts, from medical professionals to academics, to validate startup theses, but the focus will be on investing in world-class, dynamic founders.  Given how early this industry is, it’s difficult to pinpoint precisely how big the market opportunity is— but considering the large, ever-expanding applications of psychedelic medicines and therapies, the potential is nothing short of mind-boggling. The global market for drugs used in mental disorders was $70.1 billion in 2012. Just the antidepressant drug market was valued at $13.69b in 2015. More broadly, in 2019, mental health spending topped $225 Billion in the US alone. Two publicly traded psychedelic companies, both founded in the past five years, Compass Pathways and MindMed (which we were offered pre-IPO access to), have market capitalizations over $1 billion, and many more have nine-figure valuations. In contrast, the global legal marijuana market was valued at $17.7 billion in 2019. Thus, it’s hard to overstate how large and how quickly this space could grow. The priority is getting this fund to market as soon as possible, which is why we chose a Rolling Fund. Whenever possible, I will spin up SPVs for LPs that would like larger exposure to deals or when it's deemed appropriate to do follow-on investments.

Mystic Ventures

Unruly is a new investment firm, aiming to find and fund the best founders building the most innovative companies at the frontiers of what's possible today. We invest early, are not scared of risky moonshots and become your biggest fans.

Unruly Capital

Manta Ray Ventures is an early-stage venture capital fund backing mission-driven founders that provides flexible and patient capital, leveraging time, resources, and networks resources and networks as far as possible to support its portfolio companies.

Manta Ray Ventures

Freedom Biosciences

Freedom Biosciences is a biotechnology platform developing next-generation psychedelic therapeutics.

<div>Founded in 2021, Freedom Biosciences develops psychedelic-based combination therapeutics for mental health disorders such as major depressive disorder (MDD). The company&rsquo;s drug discovery platform leverages the already-known pharmacology of ketamine and other psychedelics to identify new therapies that are expected to be more effective than existing ketamine and psychedelic therapies, which are administered independently.</div>

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

Dina Burkitbayeva on LinkedIn: Freedom Biosciences Chief Medical Officer Dr. David Hough and I presented…

<div>
 
 Founded in 2021, Freedom Biosciences develops psychedelic-based combination therapeutics for mental health disorders such as major depressive disorder (MDD). The company&rsquo;s drug discovery platform leverages the already-known pharmacology of ketamine and other psychedelics to identify new therapies that are expected to be more effective than existing ketamine and psychedelic therapies, which are administered independently.
 
 
 As of August 2022, the company&rsquo;s drug pipeline included its lead candidate FREE001, a ketamine-based combination therapy that demonstrated higher durability than ketamine alone in a Phase II investigational study. The study revealed that FREE001 resulted in 14 days of antidepressant effects as opposed to just 2&ndash;7 days when ketamine is used alone.&nbsp;
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/16385">
 February 2023
 </a>
 , the company secured an undisclosed sum of investment from venture capital firm LongeVCl. This investment follow&rsquo;s the company&rsquo;s 
 <a href="https://sp-edge.com/updates/12567">
 seed funding
 </a>
 round in August 2022 which raised USD 10.5 million.
 
</div>

<div>
 
 Canadian biotech firm Core One Labs maintains three primary business operations: 1) developing novel delivery systems for psychedelic medicines, 2) psilocybin manufacturing, and 3) medical clinics to provide psychedelic-assisted psychotherapy. The company has developed proprietary technology with infused strips that dissolve immediately when placed in the patient&rsquo;s mouth to deliver molecules with a higher level of bioavailability. The company plans to advance this technology to incorporate psychedelic molecules, particularly psilocybin.&nbsp;
 
 
 Core One Labs also claims it has discovered a patentable method of producing high-quality psilocybin, which it may license to pharmaceutical companies. Additionally, the company has two psychedelic clinics in Vancouver that currently support clinical trials and maintain a database of more than 275,000 patients. The company acquired Vocan Biotechnologies and Akome Biotech in May 2021 for undisclosed amounts. Akome is developing a patent-pending psychedelic drug formulation for the treatment of Alzheimer&rsquo;s Disease.&nbsp;
 
 
 Core One Labs is listed on the Canadian Securities Exchange (CSE) and OTC markets.
 
 
</div>

Core One Labs

<div>
 
 Vancouver-based Lobe Sciences (formerly GreenStar Biosciences) is a biotechnology company developing psychedelic medicines (microdose applications) and medical devices for efficient drug delivery. The company&rsquo;s main focus is the treatment of mild traumatic brain injury and post-traumatic stress disorder (PTSD). It is also conducting early studies on psilocybin combined with N-acetylcysteine (NAC), and MDMA combined with NAC as a treatment. Lobe is also developing a patent pending nasal mist transducer device for the delivery of medicines directly to the brain&rsquo;s olfactory bulb.&nbsp;
 
 
 In June 2020, Lobe acquired Eleusian Biosciences, a company focused on the development of psychedelic medicine which expanded its intellectual property portfolio with three US patent applications for psychedelic therapeutics. Lobe is also collaborating with the University of Miami&rsquo;s Miller School of Medicine to conduct preclinical studies. After its restructuring and name change, the company started trading on the Canadian Securities Exchange (CSE) in November 2020.
 
 
 
</div>

Lobe Sciences

<div>
 
 Cybin is a psychedelic biotechnology company developing treatments for psychiatric and neurological conditions. Through its Serenity Life Science division, Cybin conducted Phase II of clinical trials on using psilocybin to treat major depressive disorder. Additionally, the company's Nature's Journey division focuses on creating non-psychedelic medicinal and nutraceutical mental health products.
 
 
 Cybin is actively building a patent portfolio, including chemically-synthesized compounds, delivery mechanisms, protocols, and new drug formulations. It has also filed an International Patent Application through the Patent Cooperation Treaty, potentially covering 153 countries.&nbsp;
 
 
 In July 2023, the company announced 
 <a href="https://sp-edge.com/updates/20076">
 EMBARKCT, 
 </a>
 a streamlined version of its EMBARK training program for pivotal studies of lead candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, respectively. In 
 <a href="https://sp-edge.com/updates/27577">
 March 2024
 </a>
 , the company received a breakthrough designation from the FDA for CYB003, and expects to initiate Phase III clinical trials for the program by mid-2024.
 
 
 Cybin implements an M&amp;A strategy to grow in the psychedelic industry. It did a reverse takeover of Charmin in June 2020, raising CAD 45 million (USD 35.5 million) for clinical studies. It acquired Adelia Therapeutics in December 2020, adding novel treatments and patent applications. Also in 
 <a href="https://sp-edge.com/updates/21335">
 August 2023 
 </a>
 it acquired 
 <a href="https://sp-edge.com/companies/470858">
 Small Pharma 
 </a>
 in an all-share transaction to strengthen its psychedelic portfolio.&nbsp;
 
 
 Founded in 2019, Cybin is listed on the NEO exchange under the ticker symbol &ldquo;CYBN&rdquo; and was uplisted to the NYSE American Stock Exchange in July 2021 under the same symbol. For FY2023, the company reported a decrease in net loss by 29.7% YoY to CAD 47.5 million (USD 35 million).&nbsp;
 Further in 
 <a href="https://sp-edge.com/updates/33849">
 September 2024
 </a>
 , it completed a 38-to-1 share consolidation of its common stock which reduced the number of outstanding common shares to ~20 million. 
 
 
 Key customers and partnerships&nbsp;
 
 
 In July 2020, Cybin expanded its operations and research activities in the European region via research partnerships and transferred its intellectual property assets to its fully-owned Irish subsidiary (formed in May 2021). In July 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/20455">
 Worldwide Clinical Trials
 </a>
 to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder. Further, in September 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/22180">
 Fluence
 </a>
 to support Cybin's EMBARK facilitator training program.
 
</div>

Cybin

<div>
 
 Canadian cannabinoid-based therapeutics company BioNxt Solutions
 (formerly Xphyto Therapeutics) announced in November 2020 that it has expanded its drug development program to incorporate a number of psychedelic compounds. This includes substances such as psilocybin, mescaline, LSD, MDMA, and DMT. Xphyto&rsquo;s initial focus is on developing standardized drug formulations with efficient delivery mechanisms for therapeutic use.
 
</div>

BioNxt Solutions

<div>
 
 New York-based Gilgamesh Pharmaceuticals is a biotechnology company developing psychedelic-inspired medicines for neuropsychiatric conditions such as depression, anxiety, addiction, and cognitive deficits. The company has three research programs in its pipeline: 1) Serotonergic Micro-Dose&ndash;a non psychedelic therapeutic treatment for attention deficit hyperactivity disorder (ADHD) and mood/anxiety disorders, 2) Arylcyclohexylamine&ndash;an improved molecule of ketamine for treatment-resistant depression and opiate use disorder, and 3) Novel Ibogaine Analogue&ndash;for the treatment of substance use disorders.&nbsp;
 
 
 Gilgamesh is one of the few psychedelic companies launched by the startup accelerator Y Combinator, and as such enjoys the accelerator&rsquo;s world-famous business expertise and network.
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/29382">
 May 2024
 </a>
 , the company partnered with AbbVie to leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel &quot;neuroplastogens.&quot; 
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27575">
 March 2024
 </a>
 , the company received a grant of&nbsp; USD 14 million from the National Institute on Drug Abuse to develop the GM-3009 compound. Prior to this, it raised USD 39 million in a 
 <a href="https://sp-edge.com/updates/15359">
 Series B 
 </a>
 funding round led by Prime Movers Lab in December 2022. 
 
</div>

Gilgamesh Pharmaceuticals

Companies conducting research on psychedelic compounds and developing novel therapeutics.

Companies operating digital platforms to deliver psychedelic therapies including psychedelic integration, virtual experiences, and mental coaching and tracking. AI drug discovery companies specializing in psychedelic therapeutics are also included.

Companies operating clinics and treatment centers to deliver psychedelic therapies.

Companies supplying psychedelic compounds through cultivation, chemical synthesis and biosynthesis for medical research and drug development.

Companies building a patent portfolio of novel analogs and derivatives of first-generation psychedelics and new drug delivery mechanisms. 

Freedom Biosciences

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless